logo
ResearchBunny Logo
Abstract
This study investigated the association between circulating tumor DNA (ctDNA) gene alterations and efficacy outcomes in the PARADIGM trial (n=733) of patients with RAS wild-type metastatic colorectal cancer (mCRC). Overall survival was prolonged with panitumumab plus modified FOLFOX6 versus bevacizumab plus modified FOLFOX6 in patients with ctDNA lacking gene alterations (median 40.7 vs 34.4 months; hazard ratio, 0.76). However, survival was similar or inferior with panitumumab in patients with ctDNA containing any alteration (19.2 vs 22.2 months; hazard ratio, 1.13). Negative hyperselection using ctDNA may guide treatment selection in mCRC.
Publisher
Nature Medicine
Published On
Mar 01, 2024
Authors
Kohei Shitara, Kei Muro, Jun Watanabe, Kentaro Yamazaki, Hisatsugu Ohori, Manabu Shiozawa, Atsuo Takashima, Mitsuru Yokota, Akitaka Makiyama, Naoya Akazawa, Hitoshi Ojima, Yasuhiro Yuasa, Keisuke Miwa, Hirofumi Yasui, Eiji Oki, Takeo Sato, Takeshi Naitoh, Yoshito Komatsu, Takeshi Kato, Ikuo Mori, Kazunori Yamanaka, Masamitsu Hihara, Junpei Soeda, Toshihiro Misumi, Kouji Yamamoto, Riu Yamashita, Kiwamu Akagi, Atsushi Ochiai, Hiroyuki Uetake, Katsuya Tsuchihara, Takayuki Yoshino
Tags
circulating tumor DNA
gene alterations
metastatic colorectal cancer
treatment efficacy
overall survival
PARADIGM trial
panitumumab
Listen, Learn & Level Up
Over 10,000 hours of research content in 25+ fields, available in 12+ languages.
No more digging through PDFs—just hit play and absorb the world's latest research in your language, on your time.
listen to research audio papers with researchbunny